Regulus Therapeutics

Business news, market intelligence, and global industry analysis.

The Latest

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Novartis headquarters building showcasing its global pharmaceutical leadership and expansion in renal disease treatments through the Regulus Therapeutics acquisition.

Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment

Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

May 2, 2025